Josh Hawley introduces bill to revoke FDA approval of mifepristone for abortions
This is performative politics again.
Sen. Josh Hawley (R-MO) introduced legislation on Wednesday that would revoke the Food and Drug Administration’s approval of mifepristone for abortion, staking out a more aggressive anti-abortion position as many Republicans aligned with President Donald Trump have preferred to avoid a new federal fight over abortion.
The measure, titled the Safeguarding Women from Chemical Abortion Act, would bar the use of mifepristone for abortion, withdraw FDA approval for the drug, and classify its distribution for abortion as a violation of federal law.
Senator Hawley Hosts Pro-Life Press Conference, Makes Major Announcement
— Senator Hawley Press Office (@SenHawleyPress) March 11, 2026
“What the bill would do is it would bar the use of mifepristone for abortion. It would withdraw the FDA approval,” Hawley said at a Capitol Hill press conference. He also said the bill would give women who took the drug the ability to sue its manufacturers, Danco Laboratories.
During an hourlong press conference, four women offered their testimonies about their experience taking the drug, in some cases under pressure to do so by former boyfriends, and about how they were left without support from abortion providers when they experienced complications from the pill.
Hawley framed the legislation as a rebuke to what he described as congressional inaction on a drug that has become central to abortion access nationwide.
“It’s vital that we give these women the ability to go to court and be made whole,” Hawley said. “My hope is to gain 60 votes. This is something for Congress to do. Congress needs to act. There’s no excuse for Congress to offload its responsibilities onto other people. Rather than being a spectator, Congress needs to act.”
Hawley’s push stands out at a moment when many Republicans, including figures in the Trump administration, have shown little appetite for sweeping new federal abortion restrictions after the Supreme Court’s 2022 Dobbs v. Jackson Women’s Health Organization decision overturned Roe v. Wade and returned the decision to the states.
Hawley, by contrast, is arguing that Congress has a direct role to play in regulating abortion drugs moving across state lines.
The bill builds on legislation Hawley rolled out last year that would have imposed stricter safeguards on mifepristone and opened the door for women to sue telehealth providers and pharmacies over complications.
At Wednesday’s event, Hawley repeatedly pointed to research …
This is performative politics again.
Sen. Josh Hawley (R-MO) introduced legislation on Wednesday that would revoke the Food and Drug Administration’s approval of mifepristone for abortion, staking out a more aggressive anti-abortion position as many Republicans aligned with President Donald Trump have preferred to avoid a new federal fight over abortion.
The measure, titled the Safeguarding Women from Chemical Abortion Act, would bar the use of mifepristone for abortion, withdraw FDA approval for the drug, and classify its distribution for abortion as a violation of federal law.
Senator Hawley Hosts Pro-Life Press Conference, Makes Major Announcement
— Senator Hawley Press Office (@SenHawleyPress) March 11, 2026
“What the bill would do is it would bar the use of mifepristone for abortion. It would withdraw the FDA approval,” Hawley said at a Capitol Hill press conference. He also said the bill would give women who took the drug the ability to sue its manufacturers, Danco Laboratories.
During an hourlong press conference, four women offered their testimonies about their experience taking the drug, in some cases under pressure to do so by former boyfriends, and about how they were left without support from abortion providers when they experienced complications from the pill.
Hawley framed the legislation as a rebuke to what he described as congressional inaction on a drug that has become central to abortion access nationwide.
“It’s vital that we give these women the ability to go to court and be made whole,” Hawley said. “My hope is to gain 60 votes. This is something for Congress to do. Congress needs to act. There’s no excuse for Congress to offload its responsibilities onto other people. Rather than being a spectator, Congress needs to act.”
Hawley’s push stands out at a moment when many Republicans, including figures in the Trump administration, have shown little appetite for sweeping new federal abortion restrictions after the Supreme Court’s 2022 Dobbs v. Jackson Women’s Health Organization decision overturned Roe v. Wade and returned the decision to the states.
Hawley, by contrast, is arguing that Congress has a direct role to play in regulating abortion drugs moving across state lines.
The bill builds on legislation Hawley rolled out last year that would have imposed stricter safeguards on mifepristone and opened the door for women to sue telehealth providers and pharmacies over complications.
At Wednesday’s event, Hawley repeatedly pointed to research …
Josh Hawley introduces bill to revoke FDA approval of mifepristone for abortions
This is performative politics again.
Sen. Josh Hawley (R-MO) introduced legislation on Wednesday that would revoke the Food and Drug Administration’s approval of mifepristone for abortion, staking out a more aggressive anti-abortion position as many Republicans aligned with President Donald Trump have preferred to avoid a new federal fight over abortion.
The measure, titled the Safeguarding Women from Chemical Abortion Act, would bar the use of mifepristone for abortion, withdraw FDA approval for the drug, and classify its distribution for abortion as a violation of federal law.
Senator Hawley Hosts Pro-Life Press Conference, Makes Major Announcement
— Senator Hawley Press Office (@SenHawleyPress) March 11, 2026
“What the bill would do is it would bar the use of mifepristone for abortion. It would withdraw the FDA approval,” Hawley said at a Capitol Hill press conference. He also said the bill would give women who took the drug the ability to sue its manufacturers, Danco Laboratories.
During an hourlong press conference, four women offered their testimonies about their experience taking the drug, in some cases under pressure to do so by former boyfriends, and about how they were left without support from abortion providers when they experienced complications from the pill.
Hawley framed the legislation as a rebuke to what he described as congressional inaction on a drug that has become central to abortion access nationwide.
“It’s vital that we give these women the ability to go to court and be made whole,” Hawley said. “My hope is to gain 60 votes. This is something for Congress to do. Congress needs to act. There’s no excuse for Congress to offload its responsibilities onto other people. Rather than being a spectator, Congress needs to act.”
Hawley’s push stands out at a moment when many Republicans, including figures in the Trump administration, have shown little appetite for sweeping new federal abortion restrictions after the Supreme Court’s 2022 Dobbs v. Jackson Women’s Health Organization decision overturned Roe v. Wade and returned the decision to the states.
Hawley, by contrast, is arguing that Congress has a direct role to play in regulating abortion drugs moving across state lines.
The bill builds on legislation Hawley rolled out last year that would have imposed stricter safeguards on mifepristone and opened the door for women to sue telehealth providers and pharmacies over complications.
At Wednesday’s event, Hawley repeatedly pointed to research …
0 Comments
0 Shares
34 Views
0 Reviews
